Delving into the Latest Updates on Shanghai Yifeng Biotechnology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Chemical drugs	1

To evaluate the safety and tolerability of different combination therapy regimens in patients with advanced malignant solid tumors who have failed standard treatment, and to determine the maximum tolerated dose (MTD) of the combination therapy or the recommended dose (RP2D) for Phase II clinical trials. To evaluate the preliminary efficacy of the combination therapy.

Start Date-

Sponsor / Collaborator

Shanghai Yifeng Biotechnology Co., Ltd.

CTR20221624

/ Not yet recruitingPhase 1

评价K-13治疗晚期恶性实体瘤患者的安全性、耐受性、药代动力学特征及初步疗效的多中心开放的I期临床试验

[Translation] A multicenter, open-label, Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of K-13 in the treatment of patients with advanced malignant solid tumors

评价在标准治疗失败的晚期恶性实体瘤患者中的安全性和耐受性，并探索最大耐受剂量（MTD），确定Ⅱ期临床试验推荐剂量。获取药代动力学特征和初步疗效。

[Translation]

To evaluate the safety and tolerability of patients with advanced malignant solid tumors who have failed standard treatment, explore the maximum tolerated dose (MTD), and determine the recommended dose for Phase II clinical trials. To obtain pharmacokinetic characteristics and preliminary efficacy.

Start Date-

Sponsor / Collaborator

Shanghai Yifeng Biotechnology Co., Ltd.

CTR20243764

/ Not yet recruitingPhase 1/2

评价K-13联合PD-1单抗、多西他赛治疗晚期恶性实体瘤患者的安全性和有效性的多中心、开放性Ib/II期临床试验

[Translation] A multicenter, open-label phase Ib/II clinical trial to evaluate the safety and efficacy of K-13 combined with PD-1 monoclonal antibody and docetaxel in the treatment of patients with advanced malignant solid tumors

评价在标准治疗失败的晚期恶性实体瘤患者中的安全性和耐受性，并探索最大耐受剂量（MTD），确定Ⅱ期临床试验推荐剂量。评价联合用药的疗效。

[Translation]

To evaluate the safety and tolerability of patients with advanced malignant solid tumors who have failed standard treatment, explore the maximum tolerated dose (MTD), and determine the recommended dose for Phase II clinical trials. To evaluate the efficacy of combined drug therapy.

Start Date-

Sponsor / Collaborator

Shanghai Yifeng Biotechnology Co., Ltd.

100 Clinical Results associated with Shanghai Yifeng Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Yifeng Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Yifeng Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Yifeng Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data